CARDIOVASCULAR RISK PROFILES OF ORAL-CONTRACEPTIVE USERS AND NONUSERS - A POPULATION-BASED STUDY

被引:7
作者
FLINT, PM
LAPANE, KL
BARBOUR, MM
DERBY, CA
CARLETON, RA
HUME, AL
机构
[1] UNIV RHODE ISL,COLL PHARM,DEPT PHARM PRACTICE,KINGSTON,RI 02881
[2] BROWN UNIV,MEM HOSP RHODE ISL,DEPT FAMILY MED,PAWTUCKET,RI 02860
[3] BROWN UNIV,MEM HOSP RHODE ISL,DIV HLTH EDUC,PAWTUCKET,RI 02860
[4] BROWN UNIV,MEM HOSP RHODE ISL,DEPT MED,PAWTUCKET,RI 02860
[5] BROWN UNIV,SCH MED,DEPT COMMUNITY HLTH,PROVIDENCE,RI 02912
关键词
D O I
10.1006/pmed.1995.1093
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. The purpose of this population-based study was to evaluate whether women taking oral contraceptive products (OCPs) have more favorable cardiovascular disease (CVD) risk profiles than women not taking OCPs. Methods. Data including sociodemographic variables and CVD risk factors from 5,239 women of reproductive age were gathered in six cross-sectional household surveys. Differences in CVD risk factor profiles between OCP users and nonusers were compared using logistic regression. Younger users and older users were compared with nonusers of the same age groups. Results. Women using OCPs (n = 807) were younger and had higher socioeconomic status than nonusers (n = 4,432). More users than nonusers were current smokers (43.1% vs 36.6%, P = 0.0011), had a total serum cholesterol level greater than or equal to 240 mg/dl (12.7% vs 6.0%, P = 0.0001), and tended to rate themselves to be at low risk for CVD (48.3% vs 45.5%, P = 0.17). Fewer OCP users than nonusers had an HDL cholesterol level less than or equal to 35 mg/dl (4.0% vs 6.9%, P = 0.0039). Conclusions. Although they tended to perceive themselves to be at low risk, women taking OCPs in this study had worse CVD risk profiles than women not reporting hormonal contraception and are candidates for cardiovascular risk reduction strategies. (C) 1995 Academic Press, Inc.
引用
收藏
页码:586 / 590
页数:5
相关论文
共 22 条
[1]  
Carleton R A, 1987, R I Med J, V70, P533
[2]   RISK-FACTORS FOR ACUTE MYOCARDIAL-INFARCTION IN WOMEN - EVIDENCE FROM THE ROYAL-COLLEGE-OF-GENERAL-PRACTITIONERS ORAL CONTRACEPTION STUDY [J].
CROFT, P ;
HANNAFORD, PC .
BRITISH MEDICAL JOURNAL, 1989, 298 (6667) :165-168
[3]   PREDICTORS OF PHYSICIANS SMOKING CESSATION ADVICE [J].
FRANK, E ;
WINKLEBY, MA ;
ALTMAN, DG ;
ROCKHILL, B ;
FORTMANN, SP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (22) :3139-3144
[4]   TRENDS IN THE CONTENT AND USE OF ORAL-CONTRACEPTIVES IN THE UNITED-STATES, 1964-88 [J].
GERSTMAN, BB ;
GROSS, TP ;
KENNEDY, DL ;
BENNETT, RC ;
TOMITA, DK ;
STADEL, BV .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1991, 81 (01) :90-96
[5]   PREVENTION OF CARDIOVASCULAR-DISEASE IN WOMEN - ROLE OF THE OBSTETRICIAN-GYNECOLOGIST [J].
GRIMES, DA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1988, 158 (06) :1662-1668
[6]  
HUME AL, 1993, PHARMACOTHERAPY, V13, P244
[7]   CONTRACEPTION AND DYSLIPIDEMIA [J].
KNOPP, RH ;
LAROSA, JC ;
BURKMAN, RT .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 168 (06) :1994-2005
[8]   ORAL CONTRACEPTION AND RISK OF A CEREBRAL THROMBOEMBOLIC ATTACK - RESULTS OF A CASE-CONTROL STUDY [J].
LIDEGAARD, O .
BRITISH MEDICAL JOURNAL, 1993, 306 (6883) :956-963
[9]  
MCKENNEY JL, 1990, HLTH ED, V21, P12
[10]   PROGESTOGENS AND CARDIOVASCULAR REACTIONS ASSOCIATED WITH ORAL-CONTRACEPTIVES AND A COMPARISON OF THE SAFETY OF 50-MU-G AND 30-MU-G ESTROGEN PREPARATIONS [J].
MEADE, TW ;
GREENBERG, G ;
THOMPSON, SG .
BRITISH MEDICAL JOURNAL, 1980, 280 (6224) :1157-1161